| (USD) | Dec 2025 | Y/Y change |
|---|---|---|
| Revenue | 13.04B | 38.42% |
| Operating expense | — | — |
| Net income | 813.57M | -959.72% |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, IVBXF returned +6.9% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +39.6% |
| 1 year | +6.9% |
| 5 years | +12.4% |
| All-time high | $13.00 (Apr 2021) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what $1,000 in IVBXF would be worth today ›No. Innovent Biologics, Inc. has not paid a dividend in the past 12 months.
Innovent Biologics, Inc. is part of the Healthcare sector.
Innovent Biologics, Inc. has a market cap of 20.55B USD, based on the latest quote.
Innovent Biologics, Inc. is scheduled to report earnings on Aug 25, 2026.
